MedPath

Impact of Splenic Artery Ligation in LDLT for Patients With Portal Hypertension

Not Applicable
Conditions
Living Donor Liver Transplantation
Interventions
Procedure: No intervention
Procedure: splenic artery ligation
Registration Number
NCT04988100
Lead Sponsor
Assiut University
Brief Summary

In this study, the investigators aim to prove that performing splenic artery ligation in living donor liver transplantation for patients with portal hypertension is beneficial for early graft function postoperatively. The investigators will be analyzing trend of LFT's (liver function tests) after surgery, time for normalization of bilirubin, INR (international normalised ratio) and decrease in ascites, morbidity, mortality, ICU (intensive care unit) and total hospital stay.

Detailed Description

Liver transplantation (LT) is the principal treatment for end-stage liver diseases and selected cases of liver neoplasms . Living donor liver transplantation (LDLT) serves as a sole source of liver graft in some countries that do not allow donation from deceased donors for cultural, social, or religious reasons.

Hyperperfusion plays an important role in liver regeneration after LDLT, but it may induce injury in the graft . After the reperfusion of a partial graft, there is a significant increase in the portal flow, but Hepatic artery flow remains constant . Excessive portal vein flow may induce injuries in grafts and may contribute to poor graft function.

For satisfactory graft function early after LT, the portal vein pressure (PVP) value after reperfusion should be \<15 mm Hg. PVP is the most important hemodynamic factor influencing the functional status of the liver and graft regeneration after LT.

The use of Splenic Artery Ligation (SAL) as a simple and safe method to modulate portal flow has been reported .

The investigators will evaluate that Splenic artery ligation in living donor liver transplantation for patients with Portal hypertension is feasible and efficient technique to improve early graft function and to decrease morbidity and hospital stay and improve outcomes .

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • All patients undergoing Living Donor Liver Transplantation(LDLT) accepted according to hospital protocol.
  • Patients who have Portal Venous Pressure (PVP) > 15 mm Hg after reperfusion .
Exclusion Criteria
  • Patients who have Portal Venous Pressure (PVP) > 15 mm Hg after reperfusion.
  • Patients who had splenectomy.
  • Patients who have splenic artery aneurysm.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
No splenic artery ligationNo interventionIf inclusion criteria are met, these group of patients will not undergo splenic artery ligation.
Patients who undergo Splenic artery ligationsplenic artery ligationIf inclusion criteria are met, these group of patients will undergo splenic artery ligation .
Primary Outcome Measures
NameTimeMethod
Incidence of early graft dysfunctionfirst postoperative month

Number of patients who develop early graft dysfunction in each group

Time to normalisation of INRfirst postoperative month

time to normalisation of INR (in days)

Time to normalisation of bilirubinfirst postoperative month

time to normalisation of bilirubin (in days)

Time to normalisation of ascites outputfirst postoperative month

time to normalisation of ascites output (in days)

Secondary Outcome Measures
NameTimeMethod
Mortalityfirst postoperative month

death

ICU stayfirst postoperative month

Duration of ICU stay (in days)

Morbidityfirst postoperative month

Morbidity as per Clavein Dindo classification

Total hospital stayfirst postoperative month

duration of total stay in hospital after liver transplantation (in days)

© Copyright 2025. All Rights Reserved by MedPath